MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA Said Cut in Hospitalizations Should be Endpoint

Loading...
Loading...
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market
MNOV
and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the third quarter ended September 30, 2012 through the filing of its quarterly report on Form 10-Q. On October 22, 2012 management met with the FDA to review future development of MN-221. Although discussions haven't been finalized, during the meeting the FDA identified the risk/benefit profile of MN-221 as a focal point for any further development of MN-221 and advised that a reduction in hospitalizations would need to be a pivotal trial primary endpoint. MediciNova is considering the design, costs, and timing of potential future clinical trials of MN-221 and will determine its development strategy following the completion of its review.
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...